Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Paulson & Co and Enzymotec Ltd (ENZY)

Enzymotec Ltd (NASDAQ:ENZY): John Paulson’s Paulson & Co filed an amended 13D.

You can check out Paulson & Co’s latest holdings and filings here.

Please follow Paulson & Co (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Paulson & Co or update its stock holdings.

John Paulson
John Paulson
Paulson & Co

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Paulson Co. Inc 2,102,990 0 2,102,990 0 2,102,990 9.17%
John Paulson
John Paulson
Paulson & Co

Page 1 of 6 – SEC Filing


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
SCHEDULE 13G
(RULE 13d – 102)
Under the Securities Exchange Act of 1934
(Amendment No. 4)*
Enzymotec Ltd.
(Name of Issuer)
Ordinary Shares, par value NIS$0.01 per share
(Title of Class of Securities)
M4059L101
(CUSIP Number)
August 23, 2017
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[x] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Enzymotec Ltd.
Trade () Now!

Page 2 of 6 – SEC Filing

1.
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Paulson & Co. Inc.
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)    [ ]
(b)    [x]
3.
SEC USE ONLY
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
State of Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
5.
SOLE VOTING POWER
2,102,990
6.
SHARED VOTING POWER
0
7.
SOLE DISPOSITIVE POWER
2,102,990
8.
SHARED DISPOSITIVE POWER
0
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,102,990
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9)
EXCLUDES CERTAIN SHARES    [ ]
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.17%
12.
TYPE OF REPORTING PERSON
IA

Follow Enzymotec Ltd.
Trade () Now!

Page 3 of 6 – SEC Filing

Item 1(a).
Name of Issuer:
Enzymotec Ltd. (the “Issuer”)
Item 1(b).
Address of Issuer’s Principal Executive Offices:
Sagi 2000 Industrial Area         P.O. Box 6        Migdal Ha’Emeq 230001, Israel
Item 2(a).
Name of Persons Filing:
Paulson & Co. Inc.
Item 2(b).
Address of Principal Business Office or, if None, Residence:
1251 Avenue of the Americas, New York, NY 10020
Item 2(c).
Citizenship:
Delaware corporation
Item 2(d).
Title of Class of Securities:
Ordinary Shares, par value NIS$0.01 per share
Item 2(e).
CUSIP Number:
M4059L101
Item 3.
If This Statement is Filed Pursuant to Rule 13d 1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
(a)
[ ]
Broker or dealer registered under Section 15 of the Exchange Act.
(b)
[ ]
Bank as defined in Section 3(a)(6) of the Exchange Act.
(c)
[ ]
Insurance company defined in Section 3(a)(19) of the Exchange Act.
(d)
[ ]
Investment company registered under Section 8 of the Investment Company Act.
(e)
[X]
Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
(f)
[ ]
Employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
(g)
[ ]
Parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
(h)
[ ]
Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
(i)
[ ]
Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
(j)
[ ]
Non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J).
(k)
[ ]
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).  If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

Follow Enzymotec Ltd.
Trade () Now!

Page 4 of 6 – SEC Filing

Item 4. Ownership.
(a)
Amount beneficially owned: 2,102,990 Ordinary Shares (see Note 1)
(b)
Percent of Class: 9.17%
The aggregate percentage of Ordinary Shares reported herein is based upon 22,852,544 shares of Ordinary Shares outstanding as of December 31, 2016 which is the total number of shares of Ordinary Shares outstanding as reported in the Issuer’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 16, 2017.
(c)
Number of shares as to which such person has:
(i)
Sole power to vote or to direct the vote: 2,102,990 Ordinary Shares.
(ii)            Shared power to vote or to direct the vote: 0
(iii)
Sole power to dispose or to direct the disposition of: 2,102,990 Ordinary Shares.
(iv)          Shared power to dispose or to direct the disposition of: 0
Note 1: Paulson & Co. Inc. (“Paulson”), an investment advisor that is registered under the Investment Advisors Act of 1940, and its affiliates furnish investment advice to and manage onshore and offshore investment funds and separate managed accounts (such investment funds and accounts, the “Funds”).  In its role as investment advisor, or manager, Paulson possesses voting and/or investment power over the securities of the Issuer described in this schedule that are owned by the Funds.  All securities reported in this schedule are owned by the Funds.  Paulson disclaims beneficial ownership of such securities.
Item 5.
Ownership of Five Percent or Less of a Class.
Not applicable.
Item 6.
Ownership of More than Five Percent on Behalf of Another Person.
The private investment funds for which Paulson & Co. Inc. acts as investment adviser have the right to participate in the receipt of dividends from, and proceeds from the sale of, the Ordinary Shares held for the accounts of such funds.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
Not applicable.
Item 8.
Identification and Classification of Members of the Group.
Not applicable.
Item 9.
Notice of Dissolution of Group.
Not applicable.

Follow Enzymotec Ltd.
Trade () Now!

Page 5 of 6 – SEC Filing

Item 10.
Certification.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Follow Enzymotec Ltd.
Trade () Now!

Page 6 of 6 – SEC Filing

SIGNATURES
After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.
Dated: September 11, 2017
PAULSON & CO. INC.
By:  /s/ Stuart L. Merzer
             Stuart L. Merzer,
            General Counsel & Chief Compliance Officer
Follow Enzymotec Ltd.
Trade () Now!